Neuro oncology News and Research

RSS

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Novel combined technique for treating neoplastic meningitis, hydrocephalus

Approximately five to ten percent of patients with primary or metastatic cancer suffer from devastating neurological complications such as headaches, seizures, confusion, difficulty swallowing and visual disturbances. These deficits are caused by a life-threatening form of brain invasion from cancer called neoplastic meningitis.

15 Jul 2011

Indirubin might help treat glioblastoma

The active ingredient in a traditional Chinese herbal remedy might help treat deadly brain tumors, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

13 Jul 2011

NewYork-Presbyterian Hospital offers two new treatment options for cancer patients

NewYork-Presbyterian Hospital has two new treatment options for patients with brain tumors and other cancers -- a next-generation radiosurgical Gamma Knife and linear accelerator.

From Elekta 11 Jul 2011

Combined pediatric neuroscience programs at Barrow Neurological Institute

St. Joseph's Hospital and Medical Center and Phoenix Children's Hospital jointly announced this week their pediatric neuroscience programs are combining under the newly formed Barrow Neurological Institute at Phoenix Children's Hospital.

24 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

Barrow Neurological Institute announces Phoenix Children’s Hospital as new pediatric affiliate

St. Joseph’s Hospital and Medical Center and Phoenix Children’s Hospital jointly announced today their pediatric neuroscience programs are combining under the newly formed Barrow Neurological Institute at Phoenix Children’s Hospital.

22 Jun 2011

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

An experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology.

17 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

New genetic test can predict clinical outcomes in glioblastoma patients

New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer, and help guide therapy, the researchers say.

1 Jun 2011

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.

10 May 2011

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

The field of adolescent and young adult oncology reflects the growing recognition that this group of patients and survivors are not just "old" pediatric patients or "young" adult patients.

9 May 2011

Targeting Aurora A gene could halt rhabdoid tumor growth in children

There are no effective treatments for rhabdoid tumors - aggressive childhood cancers that usually strike children under three years old and affect the brain or kidneys. The disease is extremely rare - fewer than 10 cases are diagnosed each year in the U.S. - but is particularly difficult to treat and almost always fatal.

6 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

Experts to present stem cell therapies for neurological disorders at Cedars-Sinai conference

Experts from stem cell programs at respected research centers around the country will present information at an April 30 conference on stem cell therapy for neurological disorders, hosted by the Department of Neurosurgery at Cedars-Sinai Medical Center in collaboration with the Genetics Policy Institute of Wellington, Fla.

29 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011